Inhibikase Therapeutics
IKT
IKT
48 hedge funds and large institutions have $106M invested in Inhibikase Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $113M → $106M (-$6.4M)
Holders
48
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$4.49M | |
| 2 | +$1.45M | |
| 3 | +$1.11M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$733K |
| 5 |
State Street
Boston,
Massachusetts
|
+$694K |
Top Sellers
| 1 | -$2M | |
| 2 | -$961K | |
| 3 | -$364K | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$353K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$340K |
